Science Explorer Back to mapMap
Discussion
Institution · Rainwater Charitable Foundation

Most cited papers from Rainwater Charitable Foundation

Rainwater Charitable Foundation

What are the most cited papers from Rainwater Charitable Foundation?

The most cited paper from Rainwater Charitable Foundation is "Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium" (Toji Miyagawa et al., 2020), with 170 citations. Next come "Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases" (83) and "The therapeutic landscape of tauopathies: challenges and prospects" (79).

Showing 31 of 31 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium Toji Miyagawa et al. · Alzheimer s & Dementia Open access 2020 170
2 Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases Eliana Marisa Ramos et al. · Alzheimer s & Dementia Open access 2020 83
3 The therapeutic landscape of tauopathies: challenges and prospects Jeffrey L. Cummings, María Isabel González, Martyn C. Pritchard et al. · Alzheimer s Research & Therapy Open access 6 Oct 2023 79
4 Current directions in tau research: Highlights from Tau 2020 Claire E. Sexton et al. · Alzheimer s & Dementia Open access 28 Sep 2021 79
5 A Brain Capital Grand Strategy: toward economic reimagination Erin M. Smith et al. · Molecular Psychiatry Open access 26 Oct 2020 79
6 The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology Bradley F. Boeve et al. · Alzheimer s & Dementia Open access 18 Oct 2019 64
7 Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH‐EXAMINER as a potential clinical trial endpoint Adam M. Staffaroni et al. · Alzheimer s & Dementia Open access 11 May 2019 51
8 Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration Nicholas T. Olney et al. · Alzheimer s & Dementia Open access 26 Nov 2019 46
9 Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort Hilary W. Heuer et al. · Alzheimer s & Dementia Open access 2020 45
10 Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration Adam M. Staffaroni et al. · Alzheimer s & Dementia Open access Jul 2019 40
11 A framework for translating tauopathy therapeutics: Drug discovery to clinical trials Howard Feldman et al. · Alzheimer s & Dementia Open access 24 Sep 2024 26
12 Nonlinear Z‐score modeling for improved detection of cognitive abnormality John Kornak et al. · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring Open access Dec 2019 26
13 Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials Glenn A. Harris, Lauren Rose Hirschfeld, María Isabel González et al. · Alzheimer s Research & Therapy Open access 3 Jun 2025 24
14 Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers Qin Chen et al. · Neurobiology of Aging Open access 15 Aug 2019 20
15 Antisense oligonucleotides provide optimism to the therapeutic landscape for tauopathies G. Harris, Lauren Rose Hirschfeld · Neural Regeneration Research Open access 10 May 2024 18
16 Novel avenues of tau research Claire E. Sexton et al. · Alzheimer s & Dementia Open access 3 Jan 2024 17
17 Quality of life and caregiver burden in familial frontotemporal lobar degeneration: Analyses of symptomatic and asymptomatic individuals within the LEFFTDS cohort Melanie Tara Gentry et al. · Alzheimer s & Dementia Open access 13 Jul 2020 13
18 Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference Bess E Frost et al. · Alzheimer s & Dementia Open access May 2025 9
19 Measuring neurofilament light in human plasma and cerebrospinal fluid: a comparison of five analytical immunoassays Udit Sheth, Rebecca Harrison, Kyle L. Ferber et al. · Clinical Chemistry and Laboratory Medicine (CCLM) Open access 8 Sep 2025 5
20 IKBKB reduces huntingtin aggregation by phosphorylating serine 13 via a non-canonical IKK pathway Cristina Cariulo, Paola Martufi, Margherita Verani et al. · Life Science Alliance Open access 8 Aug 2023 4
21 Analysis of tauopathy research funding between 2006 and 2016 reveals critical gaps in research priorities Cara M. Altimus, Kirstie E. Keller, Patrick Brannelly et al. · Alzheimer s & Dementia 9 Oct 2018 3
22 P2‐314: THE MULTIDOMAIN IMPAIRMENT RATING (MIR) SCALE: INITIAL RELIABILITY DATA ON A MULTIDIMENSIONAL SCALE DESIGNED FOR FTLD SPECTRUM DISORDERS Leah K. Forsberg et al. · Alzheimer s & Dementia Jul 2019 2
23 Emerging directions in tauopathy research Luc Buée et al. · Alzheimer s & Dementia Open access Jun 2026 1
24 The ARTFL LEFFTDS Frontotemporal Lobar Degeneration (ALLFTD) Protocol: Preliminary Data and Future Plans (2081) Bradley F. Boeve et al. · Neurology 14 Apr 2020 1
25 Studying the natural history of frontotemporal lobar degeneration (FTLD): The ARTFL LEFFTDS longitudinal FTLD (ALLFTD) protocol Bradley F. Boeve et al. · Alzheimer s & Dementia Dec 2020 1
26 From clinical phenotypes to molecular precision: multimodal biomarkers for progressive supranuclear palsy Glenn A. Harris, Lymor Barnhard, Jennifer Brummet et al. · Frontiers in Neuroscience Open access 27 Jul 2026 0
27 Insights and priorities from the 2025 private funders’ Parkinson's disease and related disorders large footprint data interoperability summit L. Kirsch, Emily G. Baxi, Mukta Phatak et al. · Journal of Parkinson s Disease Open access 10 Mar 2026 0
28 The Therapeutic Landscape of Tauopathies: Evaluating the Tau Pipeline Glenn A. Harris, Jeffrey L. Cummings, Isabel Ibarra‐González et al. · Alzheimer s & Dementia Open access Dec 2023 0
29 Gearing up for the future: Exploring facilitators and barriers to inform clinical trial design in frontotemporal lobar degeneration Yasmin B Banga et al. · Alzheimer s & Dementia Dec 2021 0
30 P2‐329: TRACKING WHITE MATTER DEGENERATION IN ASYMPTOMATIC AND SYMPTOMATIC MAPT MUTATION CARRIERS WITH DTI Qin Chen et al. · Alzheimer s & Dementia Open access Jul 2019 0
31 O4‐03‐01: FRONTOTEMPORAL LOBAR DEGENERATION RESEARCH IN NORTH AMERICA: PROGRESS IN THE ARTFL/LEFFTDS CONSORTIA Hilary W. Heuer et al. · Alzheimer s & Dementia Open access Jul 2019 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.